| FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase. | |
| | |
MedLine Citation:
|
PMID: 22251137 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH: The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS: Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A₂. CONCLUSIONS AND IMPLICATIONS: These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. |
| | |
Authors:
|
Léon J A Spijkers; Astrid E Alewijnse; Stephan L M Peters |
Related Documents
:
|
9854457 - Acute hypertension impairs endothelium-dependent vasodilation. 15838367 - Endothelin-a receptor antagonism promotes decreased vasodilation but has no differentia... 1560427 - Affective moderators of the cardiovascular response to stress in offspring of hypertens... 6947867 - Central haemodynamics and plasma prostaglandin e2 in borderline and sustained essential... 21062377 - Melanocortin signalling and the regulation of blood pressure in human obesity. 2676957 - Effect of helium-oxygen pressure on dopamine detected in vivo in the striatum of hamsters. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: British journal of pharmacology Volume: 166 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-18 Completed Date: 2012-10-09 Revised Date: 2013-06-05 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 1411-8 Citation Subset: IM |
Copyright Information:
|
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. |
Affiliation:
|
Department of Pharmacology & Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Pressure / drug effects Carotid Arteries / cytology, drug effects, metabolism*, pathology Cyclooxygenase Inhibitors / pharmacology Endothelium, Vascular / cytology, drug effects, metabolism*, pathology Enzyme Inhibitors / adverse effects, chemistry, pharmacology Hypertension / chemically induced, metabolism*, pathology, physiopathology Immunosuppressive Agents / adverse effects, chemistry, pharmacology Isoenzymes / antagonists & inhibitors, metabolism Male Muscle, Smooth, Vascular / cytology, drug effects, metabolism*, pathology Phosphorylation Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors, metabolism* Propylene Glycols / adverse effects, chemistry, pharmacology Rats Rats, Inbred SHR Rats, Inbred WKY Sphingosine / adverse effects, analogs & derivatives, chemistry, pharmacology Thromboxane A2 / antagonists & inhibitors, metabolism Vascular Resistance* / drug effects Vasoconstrictor Agents / adverse effects, chemistry, pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Cyclooxygenase Inhibitors; 0/Enzyme Inhibitors; 0/Immunosuppressive Agents; 0/Isoenzymes; 0/Propylene Glycols; 0/Vasoconstrictor Agents; 123-78-4/Sphingosine; 3QN8BYN5QF/fingolimod; 57576-52-0/Thromboxane A2; EC 2.7.1.-/Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.-/sphingosine kinase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glial cells in (patho)physiology.
Next Document: Effects of Vitamin D3 on the Expression of Growth-Related Oncogene-? in THP-1 Cells and Human Primar...